Effect of Myricetin on the Loss of Dopaminergic Neurons in the Transgenic Drosophila Model of Parkinson’s Disease

Author(s): Gulshan Ara, Mohammad Afzal, Smita Jyoti, Falaq Naz, Rahul, Yasir Hasan Siddique*

Journal Name: Current Drug Therapy

Volume 14 , Issue 1 , 2019

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: The formation of Lewy bodies is associated with the production of reactive oxygen species (ROS) and the neuronal damage specifically the dopaminergic neurons in the Parkinson’s disease patients. Hence any agent that could curtail the production of ROS /oxidative stress could act as a possible therapeutic agent thereby preventing the neuronal damage.

Method: In the present study, we first evaluated the antioxidant potential of myricetin by performing superoxide anion scavenging and diphenyl-picrylhydrazyl (DPPH) free radical scavenging assays. Myricetin at a final concentration of 10, 20 and 40µM was mixed in diet and the PD flies were allowed to feed on it for 24 days. After 24 days of exposure, the dopamine content was estimated in brain and the immunohistochemistry was performed for the tyroxine hydroxylase activity on the brain sections from each group.

Results: Myricetin showed a dose-dependent increase in the antioxidative activity. The exposure of PD flies to 10, 20 and 40µM of Myricetin not only showed a dose-dependent significant increase in the dopamine content compared to unexposed PD flies (p<0.05), but also prevented the loss of dopaminergic neurons in the brain of PD flies.

Conclusion: The results suggest that the antioxidative potential of myricetin is responsible for preventing the loss of dopaminergic neurons and dopamine content.

Keywords: Parkinson's disease, myricetin, dopamine content, dopaminergic neurons, immuno histochemistry, drosophila.

Marsh JL, Thompson LM. Drosophila in the study of neurodegenerative disease. Neuron 2006; 52: 169-78.
Chiba S, Numakawa T, Ninomiya M, Yoon HS, Hiroshi K. Cabergoline, a dopamine receptor agonist, has an antidepressant-like property and enhances brain-derived neurotrophic factor signaling. Psychopharmacology 2010; 211: 291-301.
Prasad SN. Neuroprotective effect of geraniol and curcumin in an acrylamide model of neurotoxicity in Drosophila melanogaster: Relevance to neuropathy. J Insect Physiol 2014; 60: 7-16.
Meng X, Munishkina LA, Fink AL, Uversky VN. Effects of various flavonoids on the-synuclein fibrillation process. Parkinsons Dis 2010; 2010: 1-16.
Breda C, Giorgini F, Steinert JR. Synapses and α-synuclein signalling in disease. Cogent Biol 2015; 1: 1085295.
Seidl SE, Santiago JA, Bilyk H, Potashkin JA. The emerging role of nutrition in Parkinson’s disease. Front Aging Neurosci 2014; 6: 36.
Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature 1997; 388: 839-40.
Cookson MR. The biochemistry of Parkinson’s disease. Annu Rev Biochem 2005; 74: 29-52.
Marsh JL, Thompson LM. Drosophila in the study of neurodegenerative disease. Neuron 2006; 52: 169-78.
Feany MB, Bender WWA. Drosophila model of Parkinson’s disease. Nature 2000; 404: 394-4.
Guo M. Drosophila as a model to study mitochondrial dysfunction in Parkinson’s disease. Cold Spring Harb Perspect Med 2012; 2: a009944.
Noor R, Mittal S, Iqbal J. Superoxide dismutase–applications and relevance to human diseases. Med Sci Monit 2002; 8: RA210-5.
Datla KP, Zbarsky V, Rai D, et al. Short-term supplementation with plant extracts rich in flavonoids protect nigrostriatal dopaminergic neurons in a rat model of Parkinson’s disease. J Am Coll Nutr 2007; 26: 341-9.
Siddique YH, Fatima A, Jyoti S, et al. Evaluation of the toxic potential of graphene copper nanocomposite (GCNC) in the third instar larvae of transgenic Drosophila melanogaster (hsp70-lacZ)Bg9. PLoS One 2013; 8: e80944.
Khan S, Jyoti S, Naz F, et al. Effect of L-ascorbic acid on the climbing ability and protein levels in the brain of Drosophila model of Parkinson’s disease. Int J Neurosci 2012; 122: 704-9.
Sghaier MB, Bhouri W, Neffati A, et al. Chemical investigation of different crude extracts from Teucrium ramosissimum leaves. Correlation with their antigenotoxic and antioxidant properties. Food Chem Toxicol 2011; 49: 191-201.
Wongsawatkul O, Prachayasittikul S, Isarankura-Na-Ayudhya C, et al. Vasorelaxant and antioxidant activities of Spilanthes acmella Murr. Int J Mol Sci 2008; 9: 2724-4.
Schlumpf M, Lichtensteiger W, Langemann H, Waser PG, Hefti F. A fluorometric micromethod forthe simultaneous determination of serotonin, noradrenaline and dopamine in milligram amounts of brain tissue. Biochem Pharmacol 1974; 23: 2437-46.
Palladino MJ, Keegan LP, O’Connell MA, Reenan RA. A-to-I premRNA editing in Drosophila is primarily involved in adult nervous system function and integrity. Cell 2000; 102: 437-49.
Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB. Aggregated α-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 2007; 27: 3338-46.
Trojanowski JQ, Lee VMY. Fatal attractions of proteins: A comprehensive hypothetical mechanism underlying Alzheimer’s disease and other neurodegenerative disorders. Ann N Y Acad Sci 2000; 924: 62-7.
Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease. Neurosci Lett 1992; 142: 128-30.
Recchia A, Debetto P, Negro A, Guidolin D, Skaper SD, Giusti P. α-Synuclein and Parkinson’s disease. FASEB J 2004; 18: 617-26.
Auluck PK, Chan HE, Trojanowski JQ, Lee VMY, Bonini NM. Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson’s disease. Science 2002; 295: 865-8.
Siddique YH, Naz F, Jyoti S, Ali F, Fatima A, Khanam S. Protective effect of Geraniol on the transgenic Drosophila model of Parkinson’s disease. Environ Toxicol Pharmacol 2016; 43: 225-31.
Siddique YH, Naz F, Jyoti S, Afzal M. Protective effect of apigenin in transgenic Drosophila melanogaster model of parkinson’s disease. Pharmacologyonline 2011; 23: 790-5.
Musacchio JM. Enzymes involved in the biosynthesis and degradation of catecholamines. Iverson L. Biochem Biogen Amines 2013; pp. 1-35.
Bayersdorfer F, Voigt A, Schneuwly S, Botella JA. Dopamine-dependent neurodegeneration in Drosophila models of familial and sporadic Parkinson’s disease. Neurobiol Dis 2010; 40: 113-9.
Kostrzewa RM, Kostrzewa JP, Brus R. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson’s disease. Amino Acids 2002; 23: 57-63.
Shaltiel-Karyo R, Davidi D, Menuchin Y, et al. A novel, sensitive assay for behavioral defects in Parkinson’s disease model Drosophila. Parkinsons Dis 2012; 2012: 697564.
Rubin GM, Yandell MD, Wortman JR, et al. Comparative genomics of the eukaryotes. Science 2000; 287: 2204-15.
Siddique YH, Mujtaba SF, Jyoti S, Naz F. GC-MS analysis of Eucalyptus citriodora leaf extract and its role on the dietary supplementation in transgenic Drosophila model of Parkinson’s disease. Food Chem Toxicol 2013; 55: 29-35.
Panchal K, Tiwari AK. Drosophila melanogaster “a potential model organism” for identification of pharmacological properties of plants/plant-derived components. Biomed Pharmacother 2017; 89: 1331-45.
Long J, Gao H, Sun L, Liu J, Zhao-Wilson X. Grape extract protects mitochondria from oxidative damage and improves locomotor dysfunction and extends lifespan in a Drosophila Parkinson’s disease model. Rejuvenation Res 2009; 12: 321-31.
Ara G, Afzal M, Jyoti S, Siddique YH. Effect of myricetin on the transgenic Drosophila model of Parkinson’s disease. Bull Fac Pharm Cairo Univ 2017; 55: 259-62.
Ara G, Afzal M, Jyoti S, Siddique YH. Effect of myricetin on the oxidative stress markers in the brain of transgenic flies expressing human alpha synuclein. Int J Nutr Pharmacol Neurol Dis 2017; 7: 101.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Published on: 06 March, 2019
Page: [58 - 64]
Pages: 7
DOI: 10.2174/1574885513666180529114546
Price: $65

Article Metrics

PDF: 79